Shots:

• Gilead to acquire Immunomedics for $88.00/ share representing a 108% premium to Immunomedics’ closing price on Sept 11- 2020- making a total deal value $21B. The transaction is expected to be completed in Q4’20
• The acquisition will add Immunomedic’s Trodelvy to Gilead’s portfolio- expanding its oncology pipeline and accelerated its revenue and EPS growth. Additionally- the Trodelvy is being studied in an ongoing P-III study for 3L HR+/HER2- BC and a registrational P-II study in bladder cancer- NSCLC- and other solid tumors
• Trodelvy (sacituzumab govitecan-hziy) is a Trop-2 directed ADC- received accelerated approval for mTNBC in the US while the company plans to submit the sBLA for the full approval of the therapy in Q4’20. Immunomedics is on track to file for regulatory approval in the EU in the H1’21

­ Ref: Gilead | Image: Gilead